文献速递小儿骨科骨质疏松与代谢性骨病脊柱外科

阿司福酶α治疗1年:一名16岁男性严重儿童期低磷酸酯酶症患者

Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
PubMed 文献 · Osteoporos Int · 2017-10-18

本文报告一名16岁严重儿童期低磷酸酯酶症(HPP)男性患者,15岁起接受阿司福酶α 2 mg/kg皮下注射每周三次治疗1年的临床结局。治疗3个月活动能力明显改善且无疼痛主诉,6个月可弃拐行走且影像学改善,9个月年化生长速度9.5 cm/年,但12个月脊柱侧弯从治疗前60度加重至110度并需脊柱融合手术。作者认为阿司福酶α显著改善该患者躯体功能、疼痛、整体生活质量及骨骼影像学表现,并建议对接受阿司福酶α治疗的青少年HPP患者密切监测脊柱侧弯进展。

要点

  • 16岁严重儿童期HPP男性,15岁起阿司福酶α 2 mg/kg皮下注射每周三次治疗1年。
  • 治疗3个月活动能力明显改善且无疼痛主诉,6个月可弃拐行走并与同伴参加户外活动。
  • 12个月脊柱侧弯从治疗前60度加重至110度、身高略降,需行脊柱融合手术。

核心结论

  • 作者认为,阿司福酶α治疗显著改善该患者躯体功能、疼痛、整体生活质量及骨骼影像学表现。
  • 作者建议对接受阿司福酶α治疗的青少年HPP患者密切监测脊柱侧弯进展。

研究设计与样本

  • 单例病例报告:一名16岁严重儿童期低磷酸酯酶症男性患者,15岁起接受阿司福酶α治疗并随访1年。

主要发现

  • 患者2岁时因膝内翻和乳牙早失诊断为HPP,既往多次骨折并接受16次骨科手术、下肢置入棒和针。
  • 治疗前有慢性骨骼疼痛,需拄拐行走且非常困难,15岁时身高Z评分为-5,并有严重脊柱侧弯和双下肢畸形。
  • 骨X线示矿化不足及桡骨远端和尺骨特征性透亮「舌」样改变;血清碱性磷酸酶水平稳定,血清吡哆醛5'-磷酸和尿磷酸乙醇胺升高,符合HPP。
  • 治疗3个月活动能力明显改善且无疼痛主诉;6个月可弃拐行走并与同伴参加户外活动,骨X线示原透亮区显著改善。
  • 9个月年化生长速度为9.5 cm/年,臂展生长速度为12 cm/年;12个月脊柱侧弯从治疗前60度加重至110度,身高略降,需行脊柱融合手术。

关键数值与推荐

  • 阿司福酶α剂量为2 mg/kg,皮下注射,每周三次。
  • 治疗9个月年化生长速度9.5 cm/年,臂展生长速度12 cm/年。
  • 脊柱侧弯从治疗前60度加重至治疗12个月时的110度。

临床怎么用

  • 作者建议对接受阿司福酶α治疗的青少年HPP患者密切监测脊柱侧弯进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We describe the clinical outcome of asfotase alfa therapy in a 16-year-old boy with severe childhood hypophosphatasia (HPP), who began therapy at age 15 years. The patient was diagnosed with HPP at age 2 years when he presented with genu varum and premature loss of primary teeth. He had a history of multiple fractures requiring 16 orthopedic surgeries with rod and pin placement in his lower extremities. He had chronic skeletal pain and used cane to ambulate with great difficulty. His height Z score at age 15 years was - 5. He had severe scoliosis and deformity of both legs. Bone radiograph showed hypomineralization and characteristic "tongues" of radiolucency in the distal radius and ulna. His serum alkaline phosphatase level was stable, with elevated serum pyridoxal 5'-phosphate and urine phosphoethanolamine, consistent with HPP. He was started on asfotase alfa 2 mg/kg given subcutaneously thrice weekly. He had marked clinical improvement in mobility with no report of pain after 3 months of treatment. At 6 month, he walked without cane and participated in outdoor activities with peers. Bone radiograph at 6 months showed striking improvement in previous radiolucent areas. At 9 months, his annualized growth velocity was 9.5 cm/year, while growth velocity of arm span was 12 cm/year. However, at 12 months, he was noted to have worsening scoliosis from 60 degrees before therapy to 110 degrees, with a slight decrease in height, necessitating a spinal fusion surgery. In conclusion, treatment with asfotase alfa significantly improved physical function, pain, overall quality of life, and skeletal radiographic findings in this patient. Close monitoring for progression of scoliosis in adolescents with HPP treated with asfotase alfa is recommended.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bowden SA, Adler BH. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia. Osteoporos Int. 2017. PMID: 29046930. doi:10.1007/s00198-017-4267-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。